Nonetheless, patients with CD44-positive GC in this cohort died earlier from their disease, which underlines the potency of CD44 as a tumor modulator—given the fact that downregulation of CD44 inhibits proliferation, invasion and metastasis of GC13,15,17, rendering it a potential therapeutic target for GC. This evidence concerns the gene CD44 and gastric cancer.